Paul Tudor Jones’s Structure Therapeutics GPCR Stock Holding History

Paul Tudor Jones’s Portfolio GPCR Stock Details GPCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$215K	Buy	+4,000	New	+$177K	﹤0.01%	3291

Other funds holding GPCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Jupiter Topco New York $245B AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Paul Tudor Jones's GPCR Position: Q2 2026 in Review

Paul Tudor Jones reduced its Structure Therapeutics (GPCR) stake by 29% in Q2 2026, selling an estimated $958K and leaving 53,656 shares worth $2.88M. The position accounts for ﹤0.01% of the portfolio, ranked #1680.

Paul Tudor Jones first reported a position in GPCR in Q4 2025 and has held it in 3 quarters since. The position peaked at $3.63M in Q1 2026. 192 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

Paul Tudor Jones held 53,656 shares of Structure Therapeutics worth $2.88M as of Q2 2026.
Paul Tudor Jones sold 21,645 Structure Therapeutics shares in Q2 2026, an estimated $958K.
Structure Therapeutics made up ﹤0.01% of Paul Tudor Jones's portfolio in Q2 2026, its #1680 holding.
Paul Tudor Jones first reported a position in Structure Therapeutics in Q4 2025 and has held it in 3 quarters since.
Paul Tudor Jones's Structure Therapeutics position peaked at $3.63M in Q1 2026.
192 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.